Safety follow-up study for children using lonapegsomatropin
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a child (paediatric) being treated for growth hormone deficiency (GHD) with lonapegsomatropin
- Currently receiving lonapegsomatropin as your growth treatment
- Live where the study is conducted (Europe or the USA)
- Be able and willing to sign consent/assent and follow the study follow-up visits or calls
- You should not have any reasons lonapegsomatropin is unsafe for you (such as allergy to it)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well and how safely Skytrofa (lonapegsomatropin) works for real-world patients in the U.S. It mainly gathers information from routine care to help doctors understand expected benefits and side effects.
This study is watching children who are already taking somapacitan (a growth hormone injection) to see if it is safe over a long time. It collects information about growth and any side effects.
This trial checks the long-term safety of LUM-201 in children who have idiopathic growth hormone deficiency and already completed an earlier LUM-201 study. If you previously took LUM-201 and are allowed to continue, the study may help your care team monitor ongoing effects over time.
This study follows children who are short for their age and checks how safe and effective growth hormone is over the long term. It may help families understand expected benefits and side effects for their specific growth-related condition.
This study follows adults with growth hormone deficiency who start (or have started) Sogroya to learn about its long-term safety. It does not change your treatment—it mainly checks for side effects and health outcomes over time.
This study tests whether an investigational drug can help children with idiopathic short stature (short height with no known cause) grow taller. It may be an option for children who are very short for their age and have not responded well to standard growth hormone therapy.
Hear when a new Growth Hormone Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.